Evidence map›Paper›PMID 41839922›Full record

ArticleNPJ vaccines2026

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines.

Xingru Ma, Robert D Marek, Susannah Gammell, Amanda N Summers, Tao Wang, Cong-Xiao Liu, Gangjun Lei, Junping Wei, Erika J Crosby, Amy Hobeika and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xingru Ma *Department of Pathology, Duke University, Durham, NC, USA.
Robert D Marek *Department of Pathology, Duke University, Durham, NC, USA.
Susannah GammellDepartment of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
Amanda N SummersDepartment of Surgery, Duke University, Durham, NC, USA.
Tao WangDepartment of Surgery, Duke University, Durham, NC, USA.
Cong-Xiao LiuDepartment of Surgery, Duke University, Durham, NC, USA.
Gangjun LeiDepartment of Surgery, Duke University, Durham, NC, USA.
Junping WeiDepartment of Surgery, Duke University, Durham, NC, USA.
Erika J CrosbyDepartment of Surgery, Duke University, Durham, NC, USA.
Amy HobeikaDepartment of Pathology, Duke University, Durham, NC, USA.
H Kim LyerlyDepartment of Pathology, Duke University, Durham, NC, USA.
Michael A MorseDepartment of Medicine, Duke University, Durham, NC, USA.
Zachary C HartmanDepartment of Pathology, Duke University, Durham, NC, USA. zachary.hartman@duke.edu.

Funding

NIH HHS 1 R01CA238217-01A1/02S1NIH HHS 5T32-CA009111-45Susan G. Komen KG081026U.S. Department of Defense W81XWH-20-1-0346U.S. Department of Defense W81XWH-21-2-0031
6 · The paper itself

Abstract

Self-replicating RNA vaccines delivered by viral replicon particles (VRPs) induce strong immunity, but repeated dosing on short intervals may be limited by vector responses. In patient samples and mice, VRP-srRNA vaccination generated VRP-neutralizing antibodies and T-cell responses to replicase. In mice, a third dose at two-week intervals minimally boosted transgene immunity, and prior VRP exposure reduced responses to a different-transgene VRP. Optimized schedules or heterologous prime-boost may sustain immunogenicity.

Identifiers

PMID41839922
PMCPMC13136299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.